[Thrombolysis during cardio-pulmonary resuscitation]

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Sudden cardiac death is a major cause of mortality in Europe, often due to myocardial infarction or pulmonary embolism.
• Thrombolysis is an established treatment for these conditions, but was historically contraindicated during cardiopulmonary resuscitation (CPR) due to bleeding concerns.

Purpose of the Study:

• To evaluate the efficacy and safety of thrombolysis during CPR for improving survival rates in patients experiencing sudden cardiac arrest.
• To investigate the impact of thrombolysis on cerebral microcirculation during CPR.

Main Methods:

• Review of case reports, retrospective studies, interventional trials, and experimental investigations on thrombolysis during CPR.
• Analysis of the randomized, multicenter TROICA trial evaluating tenecteplase during CPR.

Main Results:

• Previous studies suggested improved survival with thrombolysis during CPR, with no increased bleeding complications.
• Experimental data indicated improved cerebral microcirculation with thrombolysis during CPR.
• The TROICA trial found that tenecteplase alone did not significantly improve survival.

Conclusions:

• Thrombolysis during CPR is not yet standard therapy but may be considered for specific cases, especially suspected pulmonary embolism.
• Further trials combining thrombolysis with heparin and aspirin are necessary to define its role in CPR.
• Physician's individual decision-making is crucial for selected patients based on current guidelines.